- Home
- IMNM vs GPRO Comparison
IMNM vs GPRO Comparison
Compare IMNM & GPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- GPRO
- Stock Information
- Founded
- IMNM 2006
- GPRO 2004
- Country
- IMNM United States
- GPRO United States
- Employees
- IMNM N/A
- GPRO N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- GPRO Industrial Machinery/Components
- Sector
- IMNM Health Care
- GPRO Consumer Discretionary
- Exchange
- IMNM Nasdaq
- GPRO Nasdaq
- Market Cap
- IMNM 747.7M
- GPRO N/A
- IPO Year
- IMNM 2020
- GPRO 2014
- Fundamental
- Price
- IMNM $12.23
- GPRO $1.29
- Analyst Decision
- IMNM Strong Buy
- GPRO Sell
- Analyst Count
- IMNM 4
- GPRO 2
- Target Price
- IMNM $28.75
- GPRO $2.25
- AVG Volume (30 Days)
- IMNM 883.2K
- GPRO 930.1K
- Earning Date
- IMNM 11-07-2024
- GPRO 11-05-2024
- Dividend Yield
- IMNM N/A
- GPRO N/A
- EPS Growth
- IMNM N/A
- GPRO N/A
- EPS
- IMNM N/A
- GPRO N/A
- Revenue
- IMNM $10,784,000.00
- GPRO $931,412,000.00
- Revenue This Year
- IMNM N/A
- GPRO N/A
- Revenue Next Year
- IMNM N/A
- GPRO $6.42
- P/E Ratio
- IMNM N/A
- GPRO N/A
- Revenue Growth
- IMNM 62.73
- GPRO N/A
- 52 Week Low
- IMNM $6.93
- GPRO $1.16
- 52 Week High
- IMNM $30.96
- GPRO $3.80
- Technical
- Relative Strength Index (RSI)
- IMNM 36.79
- GPRO 47.48
- Support Level
- IMNM $12.24
- GPRO $1.25
- Resistance Level
- IMNM $13.40
- GPRO $1.38
- Average True Range (ATR)
- IMNM 0.77
- GPRO 0.05
- MACD
- IMNM -0.24
- GPRO -0.00
- Stochastic Oscillator
- IMNM 14.41
- GPRO 30.77
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.